Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CANbridge Approved for China Launch of First Rare Disease Treatment

publication date: Sep 9, 2020

Beijing's CANbridge Pharma was approved to launch Hunterase® (idursulfase beta injection) in China for Hunter syndrome, a rare disease. It is the first approval in CANbridge's rare disease portfolio and the first enzyme replacement therapy approved in China for Hunter syndrome. CANbridge in-licensed China rights to Hunterase in early 2019 from Korea's GC Pharma. Hunter syndrome is one of the 121 diseases on China's Rare Disease List. More details....

Stock Symbol: (KRX: 006280)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China